-
Mashup Score: 2BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff - 2 year(s) ago
Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff - 2 year(s) ago
Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
BiTE immune targeted therapy in #mCRPC. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss BiTE therapies and the #AMG160 trial. #WatchNow on UroToday > https://t.co/KseuqVqciy @PCFnews #ProstateCancer https://t.co/yhCItyALwN
-
-
Mashup Score: 0BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff - 2 year(s) ago
Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
BiTE immune targeted therapy in #mCRPC. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss BiTE therapies and the #AMG160 trial. #WatchNow on UroToday > https://t.co/KseuqVqciy @PCFnews #ProstateCancer https://t.co/gJRu3x2QIx
-
-
Mashup Score: 1BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff - 2 year(s) ago
Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
BiTE immune targeted therapy in #mCRPC. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss BiTE therapies and the #AMG160 trial. #WatchNow on UroToday > https://t.co/KseuqVqciy @PCFnews #ProstateCancer https://t.co/j6BHTa4GSd
-
-
Mashup Score: 2BiTE Immune Targeted Therapy in mCRPC - Tanya Dorff - 2 year(s) ago
Alicia Morgans and Tanya Dorff discuss the recent work on Bi-specific T-Cell antibody (BiTE) therapies. AMG160 is a half-life extended PSMA-targeted bispecific T-cell engager immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Dr. Dorff describes BiTE therapies and the AMG 160 trial. She shares PSA responses seen in patients on BiTE therapy. Dr. Dorff discusses the…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
BiTE immune targeted therapy in #mCRPC. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss BiTE therapies and the #AMG160 trial. #WatchNow on UroToday > https://t.co/KseuqVqciy @PCFnews #ProstateCancer https://t.co/1ltE8i5G67
-
BiTE immune targeted therapy in #mCRPC. @TDorffOnc @cityofhope joins @CaPsurvivorship @DanaFarber to discuss BiTE therapies and the #AMG160 trial. #WatchNow on UroToday > https://t.co/KseuqVqciy @PCFnews #ProstateCancer https://t.co/USxmQrjANW